



Antibody Derivatives As Molecular Agents for Neoplastic Targeting Consortium (ADAMANT)



consortiapedia.fastercures.org/consortia/antibody-derivatives-as-molecular-agents-for-neoplastic-targeting-consortium-adamant/

Research Areas



Tool Development

Innovation



Biomarker Research

Disease Progression, Drug



Product Development

Drugs

At a Glance

- Status: **Completed Consortium**
- Year Launched: **2008**
- Initiating Organization: **The European Union Seventh Framework Programme**
- Initiator Type: **Government**
- Location: **Europe**

Abstract

Under the umbrella of ADAMANT (Antibody Derivatives As Molecular Agents for Neoplastic Targeting), nine teams from six European countries -comprising research institutes, universities, hospitals, foundations, and small enterprises- pursued research aimed at the discovery of improved anticancer therapies, which rely on the antibody-based delivery of cytotoxic agents, radionuclides or immunostimulatory cytokines to tumour cells. The premise guiding the ADAMANT research consortium's efforts is that this targeted approach of administration spares normal tissues, reduces toxicity, and achieves unprecedented efficacy. The project has built on a multidisciplinary approach involving an already consolidated team of chemists, pharmacologists, clinicians, and clinical researchers, and endeavoured to bring the selected antibody + drug complexes from the basic research setting to the initial phases of clinical investigation.

Mission



Bearing in mind the 7-10 year time span normally needed to move a prospective agent through the pipeline and into clinical use, the benchmark of the project's success - be the transfer of at least one antibody-based tumour targeting agent to initial clinical studies - has been reached.

Consortium History

Began on April 1, 2008.

Structure & Governance

The project is governed by a consolidated team of chemists, pharmacologists, clinicians, and clinical researchers that represent different participating organizations

Financing

Three-year € 3,000,000 research project funded under the European Union's Seventh Framework Programme (FP7)

Intellectual Property

To view the research performed by ADAMANT Consortium, you must be a member

Impact/Accomplishment



For a summary of the final report, published in 2011, click [here](#)

Links/Social Media Feed

Homepage <http://www.adamant-fp7.eu/index.php>

Points of Contact

For information regarding ADAMANT, contact The European Union Commission directly

Sponsors & Partners

Raffaella Giavazzi, Coordinator, Istituto di Ricerche Farmacologiche Mario Negri

Dario Neri, ETH Zurich

Alex Berndt, Friedrich-Schiller-Universität

Matteo Zanda, Kemotech Srl

Eveline Trachsel, Philochem

Silvia Marsoni, SENDO Foundation

Barbara Pedley, University College London

Vincent Castronovo, Université de Liège

Guus Van Dongen, VU University Medical Center

Updated: **06/19/2017**